The University of Cape Town Clinical Trials Unit (UCTCTU) is based at the Desmond Tutu HIV Centre in Cape Town, South Africa. The CTU?s primary goal is to provide a highly efficient, effective, and integrated Clinical Trials Unit that contributes to the global epidemic control of HIV and Tuberculosis. The UCTCTU has the capacity, capability and competence to deliver world standard clinical trials in HIV, tuberculosis, and STI treatment and prevention in a broad range of populations. One of the core advantages of the UCTCTU is its location in Southern Africa. Recent reports estimate that of the 36.9 million people living with HIV globally, 25.7 million are living in sub-Saharan Africa. Thus, the sub- continent faces significant challenges in delivering treatments and methods of prevention but also stands to make a significant contribution to innovation and progress. In addition to its key location, the UCTCTU provides world-class scientific leadership, administrative support, and common infrastructure. This enables six well-established, diverse Clinical Research Sites to contribute cohesively to the research agenda of the four NIH funded networks. Each of the Clinical Research Sites are located in communities around Cape Town where the burden of HIV, tuberculosis and other diseases is high. Thus, the research agenda of the NIH is being fulfilled in communities where treatment and prevention is needed most. Based at the University of Cape Town, this CTU is accommodated and supported by an institution that is consistently ranked the best university in Africa, with a Health Science Faculty recently ranked in the Top 100 globally. All Clinical Research Sites have access to high-quality laboratories, with arguably the finest scientific expertise and best medical diagnostic and investigative resources in the country. The consortium of Clinical Research Sites are all components and affiliates of the University of Cape Town and thus share the same or similar management platforms, supporting and amplifying efficiencies and synergies.
The University of Cape Town Clinical Trials Unit (UCTCTU) based at the Desmond Tutu HIV Centre, University of Cape Town has six unique, expert and integrated clinical research sites which are ready and willing to contribute to the research priorities of the 4 NIH funded clinical trial Networks namely the ACTG, IMPAACT, HPTN and HVTN. Collaboratively this Clinical trials consortium will utilise the experience and expertise of the core and it?s sites to efficiently and effectively promote the research and development of new innovations in treatment, prevention and management of HIV, tuberculosis and related conditions.
|Gray, Glenda E; Mayer, Kenneth H; Elizaga, Marnie L et al. (2016) Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap. Clin Vaccine Immunol 23:496-506|
|Baeten, Jared M; Palanee-Phillips, Thesla; Brown, Elizabeth R et al. (2016) Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. N Engl J Med 375:2121-2132|
|Moodie, Zoe; Metch, Barbara; Bekker, Linda-Gail et al. (2015) Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men. PLoS One 10:e0137666|
|Bekker, Linda-Gail; Johnson, Leigh; Cowan, Frances et al. (2015) Combination HIV prevention for female sex workers: what is the evidence? Lancet 385:72-87|
|Middelkoop, Keren; Mathema, Barun; Myer, Landon et al. (2015) Transmission of tuberculosis in a South African community with a high prevalence of HIV infection. J Infect Dis 211:53-61|
|Palanee-Phillips, Thesla; Schwartz, Katie; Brown, Elizabeth R et al. (2015) Characteristics of Women Enrolled into a Randomized Clinical Trial of Dapivirine Vaginal Ring for HIV-1 Prevention. PLoS One 10:e0128857|
|Siegler, Aaron J; Voux, Alex de; Phaswana-Mafuya, Nancy et al. (2014) Elements of Condom-Use Decision Making among South African Men Who Have Sex with Men. J Int Assoc Provid AIDS Care 13:414-23|
|Boren, David; Sullivan, Patrick S; Beyrer, Chris et al. (2014) Stochastic variation in network epidemic models: implications for the design of community level HIV prevention trials. Stat Med 33:3894-904|
|Solomon, Marc M; Lama, Javier R; Glidden, David V et al. (2014) Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS 28:851-9|
|Hopkins, Kathryn L; Laher, Fatima; Otwombe, Kennedy et al. (2014) Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine induced immune responses. PLoS One 9:e103446|
Showing the most recent 10 out of 20 publications